Biotech News

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium

Adlai Nortye Ltd. (ANL)Adlai Nortye Ltd.2026-10-27 20:05 ESTConference / presentation

AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a novel CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload,

Related news

ANLAdlai Nortye Ltd.2026-10-15 11:00 EST

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

View all latest news

Adlai Nortye Ltd.

Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its story centers on trying to address difficult CNS diseases with a focused molecular approach.

Recent company news

ANLAdlai Nortye Ltd.2026-10-27 20:05 EST

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium

ANLAdlai Nortye Ltd.2026-10-15 11:00 EST

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

ANLAdlai Nortye Ltd.2026-09-30 11:00 EST

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

ANLAdlai Nortye Ltd.2026-09-08 11:00 EST

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

ANLAdlai Nortye Ltd.2026-08-14 11:00 EST

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Stock data

Close: 9.68 USD
Market cap: 745.73M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States